Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients Stefanie L. GroenlandJ. M. JanssenN. Steeghs Original Article 22 March 2023 Pages: 447 - 456
Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India Ankit PatelNiraj BhattMaulik Doshi Original Article 24 April 2023 Pages: 457 - 468
Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors Noboru YamamotoTakafumi KoyamaKentaro Yamazaki Original Article 04 May 2023 Pages: 469 - 480
Associations of plasma aprepitant and its N-dealkylated metabolite with cachexia status and clinical responses in head and neck cancer patients Yusuke SuzukiTakafumi NaitoJunichi Kawakami Original Article 04 May 2023 Pages: 481 - 490
Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor Seong JangBill StricklandJan Van Tornout Original Article Open access 06 May 2023 Pages: 491 - 499
The prevalence of end-of-life chemotherapy and targeted therapy in Japan, assessed using a health claims database Masami TsuchiyaTaku ObaraNariyasu Mano Original Article 08 May 2023 Pages: 501 - 506
Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy Samantha K. KorverJoanne M. BowenJanet K. Coller Original Article Open access 10 May 2023 Pages: 507 - 521
Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers Chaoying HuYanping ZhangLan Zhang Clinical Trial Report 11 May 2023 Pages: 523 - 529